Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies.
Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies, a provider of biopharmaceutical development and manufacturing services.
According to a company statement, Ajinomoto acquired all the capital stock of Althea for a purchase price of approximately $175 million. Althea will become a fully consolidated subsidiary of Ajinomoto Co., Inc. operating under the company name Ajinomoto Althea, Inc.
Ajinomoto Co. is a global manufacturer of seasonings, processed foods, beverages, amino acids, pharmaceuticals, and specialty chemicals. Althea Technologies is a contract development and manufacturing organization located in San Diego, providing clinical and commercial product development services.
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.